Vancouver, British Columbia--(Newsfile Corp. - February 25, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to provide an update on its business strategy and the continued development of its genomics-focused initiatives. As the Company advances its product roadmap, it remains committed to leveraging blockchain technology within its genomics platform while maintaining an Ethereum accumulation strategy as part of its treasury management.
Moss Genomics is researching and developing technology where users can receive personalized insights on their health data. Moss Genomics aims to provide individuals with a deeper understanding and control over their health data. By leveraging the Ethereum blockchain, Moss Genomics aims to allow users to maintain full control over their health information.
To support these efforts, the company has launched its new website, https://mossgenomics.com, where users can learn more about the company's genomics initiatives, sign up for product updates, and connect their Ethereum wallets in preparation for future blockchain-based features.
As previously disclosed, as part of its treasury management strategy, the Company will continue to evaluate potential investments in the blockchain and cryptocurrency sectors from time to time, including the proposed Ethereum cryptocurrency (ETH") as disclosed in the Company's news release dated February 3, 2025. Management of the Company believes that ETH represents a viable alternative to traditional fiat currencies. The Company has existing arrangements with certain service providers which permit satisfaction of payment obligations in ETH and management anticipates entering into similar arrangements in the future. The Company believes that its Ethereum treasury division is complementary to its existing business model by providing the Company with an alternative source of financing, access to a different investor base in the Ethereum community and potential for investment upside for its ETH holdings that exceed its short-term capital requirements.
Should a suitable blockchain or cryptocurrency-related investment opportunity arise-one that is unrelated to its genomics business or Ethereum treasury strategy-the Company may consider applying to the CSE to complete a change of business to that of an investment issuer. Until such time, Moss Genomics remains focused on advancing its genomics business with blockchain integration and maintaining its Ethereum treasury strategy.
The Company would like to remind investors that markets for cryptocurrencies have experienced much larger fluctuations than other markets, and there can be no assurances that significant swings in price will slow in the future. In the event that the price of cryptocurrencies decline, the value of an investment in the Company could also decline. As well, momentum pricing is typically associated with assets whose valuation, as determined by the investing public, accounts for anticipated future appreciation in value. Momentum pricing of cryptocurrency may result in speculation regarding future appreciation in the value of cryptocurrency. As a result, changing investor confidence could adversely affect an investment in the Company. Additionally, there is no assurance that cryptocurrency will become a leading means of digital payment. Any slowing or stopping of the development in the acceptance of cryptocurrency may adversely affect an investment in the Company. Furthermore, there is a risk that cryptocurrency trading platforms, or the Company's digital wallets may be compromised. Any of these events may adversely affect the operations of the Company and, consequently, its business and profitability.
About Moss Genomics Inc.
Moss Genomics is a biotechnology company focused on genomics and microbiome research to develop advanced genetic insights and solutions. The company leverages blockchain technology to enhance security and user control over genomic information. Along with its genomics-focused products, Moss Genomics deploys an Ethereum accumulation strategy as part of its treasury management, currently holding 160 ETH on its balance sheet.
For further information concerning Moss and its business, please view the Company's website at https://mossgenomics.com/ and its SEDAR+ profile at www.sedarplus.ca or contact us at:
CONTACT INFORMATION
Moss Genomics Inc.
Jack Liu, Chief Executive Officer and Director
Email: invest@mossgenomics.com
Telephone: 604-710-0124
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-Looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's intention to leverage the blockchain to advance its genomics business; the Company's belief that blockchain technology will enhance data security, privacy, and user control over genomic information; the Company's belief that its product offerings will make genetic insights more accessible and secure; the Company's belief that Ethereum will represent a viable alternative to traditional fiat currencies as part of the Company's treasury management system; and that the Company will continue to evaluate potential investments in the blockchain and cryptocurrency sectors from time to time in connection with a potential change of business.
These forward-looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the risk that the Company will be unable to utilize the blockchain in an effective manner for the advancement of its genomics business; the risk that the blockchain technology will not notably enhance data security, privacy or user control over genetic information; the risk that the Company's product offerings are unable to make genetic insights more accessible or secure; and the risk that Ethereum will not represent a viable alternative to traditional fiat currencies for use in a treasury management system.
In making the forward looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: blockchain technologies can be effectively implemented into the Company's genomics business model and can be implemented in a cost-effective and timely manner; the privacy and security offered by decentralized blockchain technology will be superior to the privacy and security over user data which may be available through other means; that the Company's use of blockchain as part of its business model will improve access to genetic insights; and that the use of Ethereum in the Company's treasury management system will reflect a viable alternative to traditional fiat currencies, including the risk that commercial partners of the Company are or become unwilling to accept Ethereum as consideration for products and services.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242214
SOURCE: Moss Genomics Inc.
